Standard BioTools
Sells retained mass-cytometry and microfluidic genomics systems after the SomaScan sale.
Something off on this page? Send us feedback.
Profile
Provides CyTOF and Hyperion mass-cytometry platforms, Biomark X9 microfluidic genomics systems, related consumables, software and services. Continuing operations are concentrated in retained life-science tools after the SomaScan sale, while the pending Treeline merger could change the listed company's identity if it closes.
Operates as a life-science-tools supplier focused on retained mass cytometry and microfluidic genomics. Current lines include CyTOF XT and CyTOF XT PRO for high-parameter single-cell analysis, Hyperion XTi for imaging mass cytometry, Biomark X9 for PCR, qPCR and NGS library-prep workflows, plus Maxpar, IMC and Advanta consumables.
Revenue comes from instruments, consumables and services, with consumables tied to active instrument use. Operations are global, but the employee base is mostly outside the United States, and manufacturing is concentrated in Singapore for microfluidics and Canada for mass-cytometry instruments and reagents.
The business excludes SomaScan after the Illumina sale. Products are sold for research use only, and the pending Treeline merger could shift the listed security from life-science tools to a Treeline-led drug-development company if it closes.
Company facts
Categories
Key statistics
Year to date −49.7% · Average volume (30d) 1.7M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating |
|---|---|---|---|---|
| Feb 27, 2025 | Keybanc | Downgrade | Overweight | Sector Weight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | −$0.01 | −$0.07 | −449.0% | $20.8M | $20.1M | −3.4% | +2.04% |
| May 5, 2026Q1 FY26 | −$0.02 | −$0.02 | 0.0% | $17.8M | $21.1M | +18.8% | −1.07% |
| Feb 24, 2026Q4 FY25 | −$0.03 | $0.06 | +300.0% | $18.5M | $23.8M | +28.6% | +1.74% |
| Nov 4, 2025Q3 FY25 | −$0.03 | −$0.04 | −60.0% | $18.5M | $19.6M | +5.7% | −4.20% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $20.2M | $21.8M | $19.6M | $23.8M | $21.1M | $20.1M | |
| Gross profit | $11.0M | $10.6M | $9.5M | $10.2M | $11.3M | $10.5M | |
| Operating income | −$24.2M | −$23.7M | −$23.5M | −$21.9M | −$9.4M | −$25.4M | |
| Net income | −$26.0M | −$33.5M | −$34.7M | $19.3M | −$45.2M | −$26.8M | |
| Diluted EPS | −$0.07 | −$0.09 | −$0.09 | $0.05 | −$0.12 | −$0.07 | |
| Gross margin | 54.6% | 48.8% | 48.5% | 43.0% | 53.5% | 52.4% | |
| Operating margin | -119.7% | -108.9% | -120.0% | -92.1% | -44.5% | -126.3% |
Fiscal years (4-quarter sums)FY21 $130.6M · FY22 $97.9M · FY23 $106.3M · FY24 $159.7M · FY25 $85.3M
Revenue by product · Q2 FY26
Revenue by geography · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $476.7M · Total debt $28.1M · Total assets $627.2M · Shareholders' equity $540.0M
Dividends
No dividends on record.
Ownership
Shares outstanding 391.46M · Float 42.77M · 10.9% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Casdin Capital, LLC | 88.78M | 22.68% | 13F | May 15, 2026 |
| Casdin Partners Master Fund, L.P. · director, 10 percent owner: | 74.91M | 19.14% | Form 4 | Dec 4, 2025 |
| Viking Global Investors LP | 58.65M | 15.00% | 13D | Jun 12, 2026 |
| MAK Capital Fund LP | 26.17M | 6.70% | 13G | May 15, 2026 |
| BlackRock, Inc. | 24.76M | 6.32% | 13F | May 13, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Dec 2, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +125,000 | $1.42 |
| Dec 3, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +75,000 | $1.44 |
| Dec 4, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +150,000 | $1.45 |
| Nov 24, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +150,000 | $1.43 |
| Nov 25, 2025 | Casdin Partners Master Fund, L.P. | director, 10 percent owner: | +7,550,000 | $1.30 |
Peers
- Thermo Fisher Scientific
Broad life-science tools overlap across cytometry, qPCR and services
- BD
Direct flow-cytometry substitute for high-parameter cell analysis
- Cytek
Pure-play spectral flow cytometry challenger to CyTOF
- Bio-Rad Laboratories
PCR and digital-PCR rival for Biomark genomics workflows
- 10x Genomics
Single-cell and spatial biology platform budget competitor
- Bruker
Spatial-biology and proteomics rival through NanoString assets
- Agilent Technologies
Genomics, cell-analysis and lab-workflow competitor
- Mesa Laboratories
Agena genomics niche competitor under a Nasdaq parent
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Standard BioTools | $0.6548 | +2.47% | $251.3M | — | — | 3.0 | −7.6% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| BD | $189.00 | −0.27% | $52.22B | 57.1 | 14.3 | 2.5 | −9.6% |
| Cytek | $4.68 | −0.21% | $604.4M | — | — | 2.9 | +5.6% |
| Bio-Rad Laboratories | $387.70 | +0.02% | $10.44B | 47.0 | 37.6 | 4.0 | −0.1% |
| 10x Genomics | $61.54 | −0.01% | $7.81B | — | — | 12.7 | −12.7% |
| Bruker | $57.08 | +0.04% | $8.69B | — | 25.2 | 2.5 | +5.2% |
| Agilent Technologies | $153.84 | +0.02% | $43.45B | 30.3 | 23.8 | 5.9 | +8.1% |
| Mesa Laboratories | $126.67 | −1.86% | $722.4M | 153.7 | 15.7 | 2.9 | +1.0% |
| Median | 47.0 | 23.7 | 3.5 | +3.1% |